Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient

Malaria Journal

Case Report

Serge Vedy¹  Nicolas Paleiron²  Jean Baptiste Roseau³  Emilie Javelle⁴  Fabrice Simon⁵  Bruno Pradines⁶  Marylin Madamet⁷ 

[1] Groupe Médico-chirurgical Bouffard, Djibouti, Republic of Djibouti;Groupe Médico-chirurgical Bouffard, Djibouti, Republic of Djibouti;Service de Pneumologie, Hôpital d’Instruction des Armées Clermont-Tonnerre, Brest, France;Service de Pneumologie, Hôpital d’Instruction des Armées Laveran, Marseille, France;Groupe Médico-chirurgical Bouffard, Djibouti, Republic of Djibouti;Service de pathologie infectieuse et tropicale, Hôpital d’Instruction des Armées Laveran, Marseille, France;Service de pathologie infectieuse et tropicale, Hôpital d’Instruction des Armées Laveran, Marseille, France;Ecole du Val de Grâce, Paris, France;Unité de Parasitologie et d’Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France;Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France;Centre National de Référence du Paludisme, Marseille, France;Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France;Centre National de Référence du Paludisme, Marseille, France;Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de Recherche Biomédicale des Armées, Hôpital d’Instruction des Armées, Marseille, France;

关键词: Malaria;    Plasmodium falciparum;    Anti-malarial;    In vitro;    Resistance;    Clinical failure;    Under-dosing;    Djibouti;    Dihydroartemisinin;    Piperaquine;   

DOI  :  10.1186/s12936-016-1535-8

 received in 2016-07-07, accepted in 2016-09-13,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundArtemisinin-based combination therapy (ACT) introduced in the mid-1990s has been recommended since 2005 by the World Health Organization as first-line treatment against Plasmodium falciparum in all endemic countries. In 2010, the combination dihydroartemisinin–piperaquine (DP) was recommended for the treatment of uncomplicated P. falciparum malaria. DP is one of the first-line treatments used by the French army since 2013.Case presentationA case of P. falciparum clinical failure with DP at day 20 was described in a 104 kg French soldier deployed in Djibouti. He was admitted to hospital for supervision of oral treatment with DP [40 mg dihydroartemisinin (DHA) plus 320 mg piperaquine tetraphosphate (PPQ)]. This corresponded to a cumulative dose of 4.6 mg/kg DHA and 37 mg/kg PPQ in the present patient, which is far below the WHO recommended ranges. No mutation was found in the propeller domain of the Kelch 13 (k13) gene, which is associated with artemisinin resistance in Southeast Asia. Pfmdr1 N86, 184F, S1034 and N1042 polymorphisms and haplotype 72–76 CVIET for the pfcrt gene were found in the present case. There was no evidence of resistance to DP.ConclusionThis case confirms the risk of therapeutic failure with dihydroartemisinin–piperaquine by under-dosing in patients weighing more than 100 kg. This therapeutic failure with DP by under-dosing highlighted the importance of appropriate dosing guidelines and the need of research data (efficacy, pharmacokinetics and pharmacodynamics) in over-weight patient group.

【 授权许可】

CC BY   
© The Author(s) 2016